A theme in which the increase in overseas projects and the growing scale and duration of contracted studies in the drug discovery support business are increasing the number of studies in progress, delaying revenue recognition until the studies are completed. Although the increase in contracted projects itself supports revenue growth, it limits the revenue impact in the current quarter in the short term.